Press "Enter" to skip to content

Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents

  • The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable mutation. 
  • Galafold is already approved in the U.S., EU, and Japan for adults who have an amenable variant or mutation.
  • The extension of the indication was supported by 1-month interim safety, and pharmacokinetics data from Study AT1001-020 evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of migalastat treatment in pediatric subjects aged 12 to less than 18 years.
  • Galafold is not approved for adolescents outside of Europe.
  • Price Action: FOLD shares are up 1.72% at $9.45 during the premarket session on the last check Monday.
  • Related content: Benzinga’s Full FDA Calendar.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *